ArticleTranslational lung cancer research2026
Increasing incidence and improved survival of leptomeningeal metastasis in advanced lung cancer: a 10-year real-world cohort study.
Article in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In advanced lung cancer, leptomeningeal metastasis (LM) is a severe complication associated with an exceptionally poor prognosis. This study investigates the incidence, histopathological features, and genetic characteristics of LM, while also examining treatment outcomes and prognostic determinants in affected patients. Methods: From January 2014 through December 2023, 8,213 patients with advanced lung cancer were evaluated, among whom 234 developed LM. The primary endpoint was overall survival (OS) in patients with advanced lung cancer complicated by LM. Results: By the data cutoff on December 28, 2023, the median follow-up was 39.5 (range: 0.2-45.0) months. The incidence of LM at initial presentation was 0.44%, with an overall incidence of 2.85%. A significant upward trend was observed, rising from 1.25% during 2014-2018 to 3.79% during 2019-2023 (P<0.05). Among patients with LM, adenocarcinoma comprised 96.6% of cases, and epidermal growth factor receptor ( Conclusions: Over the past decade, the incidence of LM in patients with advanced lung cancer has increased significantly. Targeted therapies (including dose-intensified TKIs) and ITC were strongly associated with meaningful survival improvements. While these active treatments offer substantial clinical benefits, their optimal outcomes are closely linked to favorable baseline patient characteristics, emphasizing the need for personalized multidisciplinary management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.